For Immediate Release
Chicago, IL - April 23, 2012 - Zacks.com announces the list of
stocks featured in the Analyst Blog. Every day the Zacks Equity
Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the
blog include
Allscripts Healthcare Solutions
(
MDRX
),
Apple Inc.
(
AAPL
),
Cerner Corp.
(
CERN
),
Quality Systems
(
QSII
) and
Athenahealth
(
ATHN
).
Get the most recent insight from Zacks Equity Research with the
free Profit from the Pros newsletter:
http://at.zacks.com/?id=5513
Here are highlights from Friday's Analyst Blog:
Allscripts' New iPad Application
Allscripts Healthcare Solutions
(
MDRX
), a leading player in the health care information technology
("HCIT") market, reported the launch of Allscripts Wand. It
provides clients of Allscripts Electronic Health/Medical Record
("EHR"/"EMR") an iPad application for frequently used features of
Allscripts Enterprise and Professional offerings.
The utilization of
Apple Inc.'s
(
AAPL
) iPad in healthcare is growing. It is reported that a significant
proportion of physicians own an iPad or compatible device, which is
higher than the general population.
The Wand holds intuitive appeal and permits comfortable usage
with little assistance. Two benefits from its utilization are rapid
access to data and efficient workflow. According to the company,
the Allscripts Wand is intended to provide quick access to commonly
used features of EHR.
The health care information technology market is competitive and
price sensitive. Among others, Allscripts faces strong competition
from
Cerner Corp.
(
CERN
),
Quality Systems
(
QSII
) and
Athenahealth
(
ATHN
).
However, optimism about the growth prospects of select HCIT
service providers remains high under the Obama Administration,
which passed the Stimulus package in May 2009, aimed at increasing
the use of electronic health record systems by medical
practitioners.
The company has widened its user base after its mergers with
Misys and Eclipsys and increased cross-selling opportunities.
We believe that Allscripts is well positioned in the fast growing
business of selling EHR/EMR to physician practices as well as
inpatient settings.
The acquisition of Eclipsys provides the company with an acute
care product for sale in concert with its ambulatory services. We
opine that acute and ambulatory care will continue to converge in
future and that Allscripts is well positioned to provide integrated
clinical applications that will permit health care providers to
satisfy HITECH Act requirements and eventually comply with an
outcomes-based reimbursement system.
Strong bookings currently taking place, with both ambulatory and
acute products doing well, may indicate that the Eclipsys products
are popular in the market and that cross-selling synergies are for
real.
Want more from Zacks Equity Research? Subscribe to the free
Profit from the Pros newsletter:
http://at.zacks.com/?id=5515
.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives
them keen insights to developments that affect company profits and
stock performance. Recommendations and target prices are six-month
time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides
highlights of the latest analysis from Zacks Equity Research.
Subscribe to this free newsletter today:
http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.,
which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was
the formation of his proprietary stock picking system; the Zacks
Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations
and market insights of Zacks Investment Research is through our
free daily email newsletter; Profit from the Pros. In short, it's
your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros
at
http://at.zacks.com/?id=5518
.
Visit
http://www.zacks.com/performance
for information about the performance numbers displayed in this
press release.
Follow us on Twitter:
http://twitter.com/zacksresearch
Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an
offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
APPLE INC (
AAPL
): Free Stock Analysis Report
ATHENAHEALTH IN (
ATHN
): Free Stock Analysis Report
CERNER CORP (
CERN
): Free Stock Analysis Report
ALLSCRIPTS HLTH (
MDRX
): Free Stock Analysis Report
QUALITY SYS (
QSII
): Free Stock Analysis Report
To read this article on Zacks.com click here.